Literature DB >> 15008973

T cell help is required to induce idiotypic-anti-idiotypic autoantibody network after immunization with complementary epitope 289-308aa of La/SSB autoantigen in non-autoimmune mice.

M G Papamattheou1, J G Routsias, E E Karagouni, C Sakarellos, M Sakarellos-Daitsiotis, H M Moutsopoulos, A G Tzioufas, E N Dotsika.   

Abstract

Immunotherapies against autoimmune diseases have been of limited success. Preventive vaccines could be developed on the basis to abrogate unwanted immune responses to defined autodeterminants. In this study it is shown that immunization of BALB/c mice with two linear T and B cell epitopes of the human La/SSB autoantigen (spanning the regions 289-308aa and 349-364aa) and their complementary forms specified by the complementary mRNA, results in characteristic B and T cell responses. Mice immunized with the 289-308aa epitope or its complementary peptide elicited specific antibodies against both epitopes. In contrast, mice immunized with the 349-364aa epitope or its complementary peptide mounted antibody titres against the immunizing peptide only. According to these data, the 289-308aa epitope and its complementary form were capable to generate an idiotypic-anti-idiotypic response, which were cross-regulated. Peptide-specific T cell proliferation and cytokine production in vitro revealed the induction of a two-stage T helper response (Th1-->Th2 type) after immunization with either the epitope 289-308 or its complementary peptide. IgG1 was the predominant subclass after immunization with the two forms of epitopes 289-308 and 349-364, while a response of the IgG2b > IgG2a was obtained after the immunization with the complementary form of 349-364 epitope reflecting the TH2/TH1 polarization, respectively. Our data suggest that the complementary peptides of two immunodominant epitopes of human LaSSB can mimic the autoantibodies against these epitopes and establish an active idiotypic-anti-idiotypic network.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15008973      PMCID: PMC1808979          DOI: 10.1111/j.1365-2249.2004.02356.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  58 in total

1.  Peptide carriers: A helicoid-type sequential oligopeptide carrier (SOC(n)) for multiple anchoring of antigenic/immunogenic peptides.

Authors:  M Sakarellos-Daitsiotis; V Tsikaris; P G Vlachoyiannopoulos; A G Tzioufas; H M Moutsopoulos; C Sakarellos
Journal:  Methods       Date:  1999-09       Impact factor: 3.608

2.  A peptide vaccine that prevents experimental autoimmune myasthenia gravis by specifically blocking T cell help.

Authors:  S Araga; L Xu; K Nakashima; M Villain; J E Blalock
Journal:  FASEB J       Date:  2000-01       Impact factor: 5.191

3.  A peptide based on the sequence of the CDR3 of a murine anti-DNA mAb is a better modulator of experimental SLE than its single amino acid-substituted analogs.

Authors:  N Brosh; H Zinger; M Fridkin; E Mozes
Journal:  Cell Immunol       Date:  2000-10-10       Impact factor: 4.868

4.  The mechanism by which a peptide based on complementarity-determining region-1 of a pathogenic anti-DNA auto-Ab ameliorates experimental systemic lupus erythematosus.

Authors:  E Eilat; M Dayan; H Zinger; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

5.  Cognate T cell help is sufficient to trigger anti-nuclear autoantibodies in naive mice.

Authors:  C L Keech; A D Farris; D Beroukas; T P Gordon; J McCluskey
Journal:  J Immunol       Date:  2001-05-01       Impact factor: 5.422

6.  Study of antibody and T cell responses in rabbits immunized with synthetic human B cell epitope analogues of La (SSB) autoantigen.

Authors:  E Yiannaki; P G Vlachoyiannopoulos; M N Manoussakis; C Sakarellos; M Sakarellos-Daitsiotis; H M Moutsopoulos; A G Tzioufas
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

7.  Unmasking the anti-La/SSB response in sera from patients with Sjogren's syndrome by specific blocking of anti-idiotypic antibodies to La/SSB antigenic determinants.

Authors:  John G Routsias; Evgenia Touloupi; Eleni Dotsika; Avrilia Moulia; Vassilios Tsikaris; Constantinos Sakarellos; Maria Sakarellos-Daitsiotis; Haralampos M Moutsopoulos; Athanasios G Tzioufas
Journal:  Mol Med       Date:  2002-06       Impact factor: 6.354

Review 8.  Sjögren's syndrome: autoantibodies to cellular antigens. Clinical and molecular aspects.

Authors:  C P Mavragani; A G Tzioufas; H M Moutsopoulos
Journal:  Int Arch Allergy Immunol       Date:  2000-09       Impact factor: 2.749

9.  Prevention and reversal of experimental autoimmune myasthenia gravis by a monoclonal antibody against acetylcholine receptor-specific T cells.

Authors:  L Xu; M Villain; F S Galin; S Araga; J E Blalock
Journal:  Cell Immunol       Date:  2001-03-15       Impact factor: 4.868

10.  Effect of aging on cytokine production in normal and experimental systemic lupus erythematosus-afflicted mice.

Authors:  M Dayan; R Segal; A Globerson; B Habut; G M Shearer; E Mozes
Journal:  Exp Gerontol       Date:  2000-03       Impact factor: 4.032

View more
  4 in total

Review 1.  Protective role of anti-idiotypic antibodies in autoimmunity--lessons for type 1 diabetes.

Authors:  Christiane S Hampe
Journal:  Autoimmunity       Date:  2012-02-23       Impact factor: 2.815

2.  ANCA patients have T cells responsive to complementary PR-3 antigen.

Authors:  Jiajin Yang; David J Bautz; Sofia Lionaki; Susan L Hogan; Hyunsook Chin; Roland M Tisch; John L Schmitz; Barrak M Pressler; J Charles Jennette; Ronald J Falk; Gloria A Preston
Journal:  Kidney Int       Date:  2008-07-02       Impact factor: 10.612

Review 3.  Autoantigen complementarity: a new theory implicating complementary proteins as initiators of autoimmune disease.

Authors:  William F Pendergraft; Barrak M Pressler; J Charles Jennette; Ronald J Falk; Gloria A Preston
Journal:  J Mol Med (Berl)       Date:  2004-12-11       Impact factor: 4.599

Review 4.  Molecular recognition theory and sense-antisense interaction: therapeutic applications in autoimmunity.

Authors:  Matthew Thomas Hardison; James Edwin Blalock
Journal:  Front Biosci (Elite Ed)       Date:  2012-01-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.